In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci

A 24-country study

Richard V. Goering, C. E. Nora, R. Hare, F. Sabatelli, K. Aldridge, P. Della-Latta, J. Dick, M. J. Ferraro, J. Hindler, D. Bruckner, M. Jacobs, R. Jones, D. Low, A. Medeiros, J. Boyce, B. Murray, F. Baquero, D. Costa, N. Frimodt-Moller, H. Goossens & 19 others D. Graninger, S. Gudmundsson, D. Gur, P. Huovinen, M. Kettner, E. Keuleyan, K. Klugman, R. Le Clercq, J. Patzer, G. Petrikkos, E. Lingas, C. E. Nord, G. Reshedko, L. Stratchounski, J. Schindler, G. C. Schito, J. Verhoef, B. Wiedermann, R. Wise

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective. To collect and analyze data on susceptibility of methicillin-resistant staphylococci to evernimicin and other antimicrobial agents. Methods. Pecent clinical isolates of methicillin-resistant staphylococci from 33 laboratories in North America, Europe and South Africa were investigated. Results. Of the antimicrobial agents tested, evernimicin had the lowest MIC90s for methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci (0.75 and 1.0 mg/L, respectively). Resistance to ciprofloxacin and erythromycin was widespread, with higher levels of resistance in North America than in other regions. Conclusions. Susceptibility surveys help to determine the antimicrobial activity of new agents. Ciprofloxacin- and erythromycin-resistant staphylococci were prevalent throughout all regions.

Original languageEnglish
Pages (from-to)549-556
Number of pages8
JournalClinical Microbiology and Infection
Volume6
Issue number10
DOIs
StatePublished - Oct 2000

Fingerprint

Methicillin Resistance
Staphylococcus
Anti-Bacterial Agents
Erythromycin
Ciprofloxacin
North America
Anti-Infective Agents
Northern Africa
Coagulase
Methicillin-Resistant Staphylococcus aureus
South Africa
In Vitro Techniques
evernimicin

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Microbiology

Cite this

In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci : A 24-country study. / Goering, Richard V.; Nora, C. E.; Hare, R.; Sabatelli, F.; Aldridge, K.; Della-Latta, P.; Dick, J.; Ferraro, M. J.; Hindler, J.; Bruckner, D.; Jacobs, M.; Jones, R.; Low, D.; Medeiros, A.; Boyce, J.; Murray, B.; Baquero, F.; Costa, D.; Frimodt-Moller, N.; Goossens, H.; Graninger, D.; Gudmundsson, S.; Gur, D.; Huovinen, P.; Kettner, M.; Keuleyan, E.; Klugman, K.; Le Clercq, R.; Patzer, J.; Petrikkos, G.; Lingas, E.; Nord, C. E.; Reshedko, G.; Stratchounski, L.; Schindler, J.; Schito, G. C.; Verhoef, J.; Wiedermann, B.; Wise, R.

In: Clinical Microbiology and Infection, Vol. 6, No. 10, 10.2000, p. 549-556.

Research output: Contribution to journalArticle

Goering, RV, Nora, CE, Hare, R, Sabatelli, F, Aldridge, K, Della-Latta, P, Dick, J, Ferraro, MJ, Hindler, J, Bruckner, D, Jacobs, M, Jones, R, Low, D, Medeiros, A, Boyce, J, Murray, B, Baquero, F, Costa, D, Frimodt-Moller, N, Goossens, H, Graninger, D, Gudmundsson, S, Gur, D, Huovinen, P, Kettner, M, Keuleyan, E, Klugman, K, Le Clercq, R, Patzer, J, Petrikkos, G, Lingas, E, Nord, CE, Reshedko, G, Stratchounski, L, Schindler, J, Schito, GC, Verhoef, J, Wiedermann, B & Wise, R 2000, 'In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: A 24-country study', Clinical Microbiology and Infection, vol. 6, no. 10, pp. 549-556. https://doi.org/10.1046/j.1469-0691.2000.00167.x
Goering, Richard V. ; Nora, C. E. ; Hare, R. ; Sabatelli, F. ; Aldridge, K. ; Della-Latta, P. ; Dick, J. ; Ferraro, M. J. ; Hindler, J. ; Bruckner, D. ; Jacobs, M. ; Jones, R. ; Low, D. ; Medeiros, A. ; Boyce, J. ; Murray, B. ; Baquero, F. ; Costa, D. ; Frimodt-Moller, N. ; Goossens, H. ; Graninger, D. ; Gudmundsson, S. ; Gur, D. ; Huovinen, P. ; Kettner, M. ; Keuleyan, E. ; Klugman, K. ; Le Clercq, R. ; Patzer, J. ; Petrikkos, G. ; Lingas, E. ; Nord, C. E. ; Reshedko, G. ; Stratchounski, L. ; Schindler, J. ; Schito, G. C. ; Verhoef, J. ; Wiedermann, B. ; Wise, R. / In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci : A 24-country study. In: Clinical Microbiology and Infection. 2000 ; Vol. 6, No. 10. pp. 549-556.
@article{4026752cd61a4a2695ee351931e0fefb,
title = "In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: A 24-country study",
abstract = "Objective. To collect and analyze data on susceptibility of methicillin-resistant staphylococci to evernimicin and other antimicrobial agents. Methods. Pecent clinical isolates of methicillin-resistant staphylococci from 33 laboratories in North America, Europe and South Africa were investigated. Results. Of the antimicrobial agents tested, evernimicin had the lowest MIC90s for methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci (0.75 and 1.0 mg/L, respectively). Resistance to ciprofloxacin and erythromycin was widespread, with higher levels of resistance in North America than in other regions. Conclusions. Susceptibility surveys help to determine the antimicrobial activity of new agents. Ciprofloxacin- and erythromycin-resistant staphylococci were prevalent throughout all regions.",
author = "Goering, {Richard V.} and Nora, {C. E.} and R. Hare and F. Sabatelli and K. Aldridge and P. Della-Latta and J. Dick and Ferraro, {M. J.} and J. Hindler and D. Bruckner and M. Jacobs and R. Jones and D. Low and A. Medeiros and J. Boyce and B. Murray and F. Baquero and D. Costa and N. Frimodt-Moller and H. Goossens and D. Graninger and S. Gudmundsson and D. Gur and P. Huovinen and M. Kettner and E. Keuleyan and K. Klugman and {Le Clercq}, R. and J. Patzer and G. Petrikkos and E. Lingas and Nord, {C. E.} and G. Reshedko and L. Stratchounski and J. Schindler and Schito, {G. C.} and J. Verhoef and B. Wiedermann and R. Wise",
year = "2000",
month = "10",
doi = "10.1046/j.1469-0691.2000.00167.x",
language = "English",
volume = "6",
pages = "549--556",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci

T2 - A 24-country study

AU - Goering, Richard V.

AU - Nora, C. E.

AU - Hare, R.

AU - Sabatelli, F.

AU - Aldridge, K.

AU - Della-Latta, P.

AU - Dick, J.

AU - Ferraro, M. J.

AU - Hindler, J.

AU - Bruckner, D.

AU - Jacobs, M.

AU - Jones, R.

AU - Low, D.

AU - Medeiros, A.

AU - Boyce, J.

AU - Murray, B.

AU - Baquero, F.

AU - Costa, D.

AU - Frimodt-Moller, N.

AU - Goossens, H.

AU - Graninger, D.

AU - Gudmundsson, S.

AU - Gur, D.

AU - Huovinen, P.

AU - Kettner, M.

AU - Keuleyan, E.

AU - Klugman, K.

AU - Le Clercq, R.

AU - Patzer, J.

AU - Petrikkos, G.

AU - Lingas, E.

AU - Nord, C. E.

AU - Reshedko, G.

AU - Stratchounski, L.

AU - Schindler, J.

AU - Schito, G. C.

AU - Verhoef, J.

AU - Wiedermann, B.

AU - Wise, R.

PY - 2000/10

Y1 - 2000/10

N2 - Objective. To collect and analyze data on susceptibility of methicillin-resistant staphylococci to evernimicin and other antimicrobial agents. Methods. Pecent clinical isolates of methicillin-resistant staphylococci from 33 laboratories in North America, Europe and South Africa were investigated. Results. Of the antimicrobial agents tested, evernimicin had the lowest MIC90s for methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci (0.75 and 1.0 mg/L, respectively). Resistance to ciprofloxacin and erythromycin was widespread, with higher levels of resistance in North America than in other regions. Conclusions. Susceptibility surveys help to determine the antimicrobial activity of new agents. Ciprofloxacin- and erythromycin-resistant staphylococci were prevalent throughout all regions.

AB - Objective. To collect and analyze data on susceptibility of methicillin-resistant staphylococci to evernimicin and other antimicrobial agents. Methods. Pecent clinical isolates of methicillin-resistant staphylococci from 33 laboratories in North America, Europe and South Africa were investigated. Results. Of the antimicrobial agents tested, evernimicin had the lowest MIC90s for methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative staphylococci (0.75 and 1.0 mg/L, respectively). Resistance to ciprofloxacin and erythromycin was widespread, with higher levels of resistance in North America than in other regions. Conclusions. Susceptibility surveys help to determine the antimicrobial activity of new agents. Ciprofloxacin- and erythromycin-resistant staphylococci were prevalent throughout all regions.

UR - http://www.scopus.com/inward/record.url?scp=0034309817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034309817&partnerID=8YFLogxK

U2 - 10.1046/j.1469-0691.2000.00167.x

DO - 10.1046/j.1469-0691.2000.00167.x

M3 - Article

VL - 6

SP - 549

EP - 556

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 10

ER -